These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11347724)

  • 21. Efficacy and safety of twice-daily versus three-times daily saquinavir soft gelatin capsules as part of triple combination therapy for HIV-1 infection.
    Wheat LJ; Farthing C; Cohen C; Pierone G; Lalezari J; Pilson RS; Siemon-Hryczyk P;
    Antivir Ther; 2002 Sep; 7(3):199-209. PubMed ID: 12487388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
    Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P
    J Acquir Immune Defic Syndr; 2002 Apr; 29(5):464-70. PubMed ID: 11981362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1.
    Pai MP; Schriever CA; Diaz-Linares M; Novak RM; Rodvold KA
    Pharmacotherapy; 2004 May; 24(5):592-9. PubMed ID: 15162893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety profile of soft gelatin formulation of saquinavir in combination with nucleosides in a broad patient population. NV15182 Study Team.
    Gill MJ
    AIDS; 1998 Jul; 12(11):1400-2. PubMed ID: 9708428
    [No Abstract]   [Full Text] [Related]  

  • 25. The safety and antiviral effect of protease inhibitors in children.
    Temple ME; Koranyi KI; Nahata MC
    Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous determination of the new HIV protease inhibitor lopinavir (ABT 378) and of indinavir(1), amprenavir, saquinavir, ritonavir (ABT 538)(2) and nelfinavir(3) in human plasma by gradient HPLC.
    Kuschak D; Mauss S; Schmutz G; Gantke B
    Clin Lab; 2001; 47(9-10):471-7. PubMed ID: 11596909
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
    van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Value of saquinavir in antiretroviral treatment of adult HIV-1 infection in 2001].
    Léautez S; Billaud E
    Presse Med; 2001 Sep; 30(26):1299-303. PubMed ID: 11603093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saquinavir-soft gel: establishing saquinavir in HAART regimens.
    Moyle GJ
    Expert Opin Investig Drugs; 1998 Aug; 7(8):1313-22. PubMed ID: 15992033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults.
    Kilby JM; Sfakianos G; Gizzi N; Siemon-Hryczyk P; Ehrensing E; Oo C; Buss N; Saag MS
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2672-8. PubMed ID: 10991842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nelfinavir. A review of its therapeutic efficacy in HIV infection.
    Jarvis B; Faulds D
    Drugs; 1998 Jul; 56(1):147-67. PubMed ID: 9664204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology and clinical experience with saquinavir.
    Kravcik S
    Expert Opin Pharmacother; 2001 Feb; 2(2):303-15. PubMed ID: 11336588
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.
    Jensen-Fangel S; Kirk O; Blaxhult A; Gerstoft J; Pedersen C; Black FT; Lundgren JD; Obel N
    HIV Clin Trials; 2001; 2(2):122-7. PubMed ID: 11590520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
    Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents.
    Hsu A; Granneman GR; Bertz RJ
    Clin Pharmacokinet; 1998 Oct; 35(4):275-91. PubMed ID: 9812178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Saquinavir: a review of its use in boosted regimens for treating HIV infection.
    Plosker GL; Scott LJ
    Drugs; 2003; 63(12):1299-324. PubMed ID: 12790697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease inhibitor-naive HIV-positive patients.
    Hellinger J; Cohen C; Morris A; Sheble-Hall S; Gordon D; Foy C; Jackson-Pope L; Shevitz A; van Schaic E
    HIV Clin Trials; 2005; 6(2):107-17. PubMed ID: 15983895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical use of a simultaneous HPLC assay for indinavir, saquinavir, ritonavir and nelfinavir in children and adults.
    Walson PD; Cox S; Utkin I; Gerber N; Crim L; Brady M; Koranyi K
    Ther Drug Monit; 2003 Dec; 25(6):650-6. PubMed ID: 14639050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
    Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.